Marijuana - Public Weed Stocks & Analysis

[MrPojax]

(CHV) or (SARSF) is UnderValued and is gonna be $2-$3 with sales license.

- 3 amazing Divisions

- Abba Medix: Cultivation license - Soon to have Sales License, extraction etc.!

- Marijuana for Trauma - 11 medical Marijuana clinics aimed at Veterans. 4 more to come.

- Knalysis Technologies - Tech for the MJ space.

See Article: http://thedeepdive.ca/canada-house-wellness-undervalued/

Canada House Wellness – The Undervalued Cannabis Player




Here is some DD

Robertson15 wrote:

Hey guys, heres a due diligence write up on CHV to keep on your radar!

CHV Sp is .46 Trading. Cultivation license already with sales license on the way! Theyre applying for an extraction license this week also. Including a joint venture for edibles and oil with EAT (Nutritional High)...Also in talks to expand to a possible 90k sqf at their current leased property or aquiring elsewhere!

Canada House Wellness Group Inc

CHV have 3 divisions with (11) clinics and additional 4 more soon, growing, and tech which are Marijuana for Trauma Cannabis Wellness Clinics, Abba Medix Corp. Licensed Producer and Knalysis Technologies Data Analytics.
Marijuana for Trauma Cannabis Wellness Clinics provide services to its clients include:
• Documentation of a client’s medical history and current condition;
• Evaluation of their current condition and meds taken;
• Discussion of possible cannabis alternatives to consider;
• Assistance in obtaining a medical cannabis prescription;
• Assistance in identifying a “best fit” cannabis strain and vendor selection;
• Evaluation of treatment results, with the objective of establishing each client’s optimum benefit routine; and
• Counseling on how a client can take full advantage of any insurance and disability benefits that may be available.
Abba Medix Craft Cannabis Licensed Producer: Abba projects that it will complete its required two grow cycles and will have received its License to Sell and be fully operational by the end of Q2 2018, at a cost of approximately $5 million, a significant portion of which is already in place.
Abba will then offer a fully integrated seed to sale vertical with the benefit of an API that will link directly to the Cannabis Patient Management patient services and software provided by its sister company, Marijuana for Trauma – now with more than 7,000 active clients.
They have been issued permits from Health Canada and the Canadian Food Inspection Agency to import its selected starting genetics.
These genetics are scheduled to arrive in February. Abba looks to have two lots of cannabis harvested and ready for Health Canada approval by the end of June and anticipates receiving a License to Sell by July. Abba then expects to be in full production by September of this year.
At full production, Abba’s current grow operations are projected to produce more than 2,100 kg annually.
Knalysis Technologies Data Analytics: It created its smartphone Wellness Tracker to provide an essential treatment-results-treatment refinement feedback loop to refine its data sets.
For its sister company, MFT, it created its HIPPA-compliant Cannabis Patient Management software that seamlessly links MFT with its patients, physicians, and other care providers, a global approach to reporting, monitoring and care. Its leadership team envisioned a need for health technology connecting every aspect of the medical marijuana field, and has pioneered software developed to deliver better monitoring of symptoms, moods, and treatments for both physician and patient. Knalysis principals are industry veterans in technology, data collection, business applications, and the medical marijuana vertical
Has more than 12,000 medical cannabis patients on its software platforms representing 6% of the registered base in all of Canada. Coupled with Knalysis’ US client base, more than 32 million data points for medical cannabis treatment have been captured to date.
As patient count in the Knalysis platforms continues to increase by approximately 2,500 per month, it is now seeing the impact of having big data at its fingertips.
Knalysis is also gaining traction with several potential new cannabis clinic clients which would add another 10,000 – 20,000 patients into its platforms by mid-year, adding 10s of millions more data points for the benefit of its analytics subscribers.
CHV also expects license to sell, and applied for extraction license.